Lilly to acquire Kelonia Therapeutics for in vivo CAR-T cell therapy advancement
Lilly is acquiring Kelonia Therapeutics to enhance its portfolio in in vivo CAR-T cell therapies, particularly targeting relapsed/refractory multiple myeloma.
Asset / Drug
Drug and asset intelligence for KLN-1010 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.